BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, June 7, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2007

View Archived Issues

Tego and NCI collaborate on development of fullerene formulation

Read More

Gilead reports promising phase III results for chronic hepatitis B

Read More

CytRx identifies arimoclomol dose for phase IIb trial

Read More

Positive phase I findings for topical antibiotic REP-8839

Read More

OBE-101 phase II obesity trial completes treatment

Read More

Beta-secretase inhibitor CTS-21166 begins initial phase I study

Read More

New trials commence for Heplisav

Read More

Roche completes acquisition of BioVeris

Read More

Ketasyn advances for the treatment of Alzheimer's disease

Read More

Enrollment opens for phase IIa study of KP-1461 in HIV

Read More

Intradigm selects Agilent for siRNA manufacturing

Read More

Positive results for deCODE's drug candidate DG-041 for arterial thrombosis

Read More

Molecular Insight initiates phase II pivotal registration trial for Zemiva

Read More

UCB and Biogen Idec's initiate phase II study of CDP-323 for MS

Read More

Novel SGLT inhibitors reduce postprandrial hyperglycemia in diabetic rats

Read More

DPP-IV inhibition with S-40010 enhances pancreatic beta-cell mass and reduces postprandrial glycemia

Read More

PSN-119-1: A GPR119 receptor agonist with antidiabetic and antiobesity properties

Read More

Positive results with novel selective PPARalpha agonist in diabetic monkeys

Read More

Potential targets for the treatment of sleep disorders

Read More

Amgen's new TRPV1 antagonist shows analgesic efficacy in rat pain models

Read More

Novel agents for HIV infection reported in recent Bristol-Myers Squibb patent

Read More

Novel analgesic agents imparted in recent Novartis and Novartis Pharma patents

Read More

Priority review granted for Isentress

Read More

New therapeutic agents for neurological disorders reported in recent patents

Read More

Rotarix filed for U.S. approval

Read More

Supplemental NDA filed for Nexavar in hepatocellular carcinoma

Read More

Tasigna submitted in Japan

Read More

Actos filed for use in combination with insulin in Japan

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2026.
  • New York University identifies new analogues of mannose-6-phosphate

    BioWorld Science
    New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
  • Liver disease

    FB-7033 demonstrates efficacy in MASH management

    BioWorld Science
    17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
  • Illustration of antibody carrying radioactive isotope

    Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC

    BioWorld Science
    At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
  • Bial-Portela discovers new OX1 receptor antagonists

    BioWorld Science
    Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing